SOURCE: FONAR Corporation

FONAR Corporation

May 15, 2013 07:00 ET

FONAR Announces Fiscal 2013 3rd Quarter and Nine Month Earnings Report; Total Assets Double; 3rd Quarter Revenues Increase 22% and 7th Straight Quarter of $1.5 Million of Net Income

MELVILLE, NY--(Marketwired - May 15, 2013) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning™, reported its 3rd quarter fiscal 2013 and nine month financial results today, for the period ended March 31, 2013. The Company's two industry segments are: Development, manufacturing and servicing of the UPRIGHT® Multi-Position™ MRI, and management of 23 Stand-Up® MRI, (UPRIGHT® MRI) centers.

Third Quarter Highlights

During the quarter the Company's subsidiary, HMCA, entered into an agreement with outside investors to acquire a 50.5% controlling interest in a newly formed limited liability company, Health Diagnostics Management, LLC (HDM). HMCA contributed $20.2 million to HDM and the group of outside investors contributed $19.8 million for its non-controlling membership interest. 

On March 5, 2013, HDM purchased from Health Diagnostics, LLC and certain of its subsidiaries (HD), a business managing 12 Stand-Up® MRI centers and two other scanning centers located in the states of New York and Florida.

With the purchase of HD, the Company increased total assets to $73.3 million at March 31, 2013. This compares to total assets of $33.6 million at June 30, 2012, an increase of 118%. Meanwhile, total liabilities increased to $38.3 million at March 31, 2013 as compared to $22.5 million on June 30, 2012, an increase of 70%. Stockholder's equity increased to $35.0 million at March 31, 2013 from $11.1 million on June 30, 2012, an increase of 216%. 

FONAR continued on its surge of profitable quarters where net income was greater than $1.5 million, climbing to seven straight quarters. The Company has had 13 straight quarters of income from operations. 

Revenues increased 22% to $11.6 million for the quarter ended March 31, 2013, an increase of 21% from $9.6 million for the preceding quarter ending December 31, 2012. The revenues for this quarter are the largest quarterly revenue since the Nation's 2008 financial crisis. Approximately $2.8 million of revenue was from the acquisition of HD.

Statement of Operations Items

Net income for the quarters ended March 31, 2013 and March 31, 2012 was $1.6 million. Net income for the nine months ended March 31, 2013 was $5.0 million, as compared to $5.1 million for the nine-month period ended March 31, 2012. Net income for the quarter ended March 31, 2013 included only 3 weeks of the net income of HDM which was acquired on March 5, 2013.

Income from operations for the quarters ended March 31, 2013 and March 31, 2012, was $1.6 million. Income from operations for the nine months ended March 31, 2013, was $5.2 million, as compared to $5.3 million, for the nine-month period ended March 31, 2012.

Total revenues, for the quarter ended March 31, 2013, increased 22% to $11.6 million, as compared to the quarter ended March 31, 2012, when total revenues were $9.5 million. Total revenues, for the nine months ended March 31, 2013, increased 8% to $30.8 million, as compared to the nine months ended March 31, 2012, when total revenues were $28.5 million.

Basic net income per common share for the quarter ended March 31, 2013, was $0.17, as compared to $0.21 for the quarter ended March 31, 2012. Diluted net income per common share for the quarter ended March 31, 2013, was $0.17, as compared to $0.20 for the quarter ended March 31, 2012.

Basic net income per common share for the nine months ended March 31, 2013, was $0.61, as compared to $0.71 for the nine months ended March 31, 2012. Diluted net income per common share for the nine months ended March 31, 2013, was $0.60, as compared to $0.69 for the nine months ended March 31, 2012.

Revenues from the HMCA management and other fees segment which manages the FONAR UPRIGHT® Multi-Position™ MRI diagnostic imaging centers, increased 42% to $7.4 million for the three months ended March 31, 2013, from $5.2 million for the three-month period ended March 31, 2012. In addition, revenues from a new category called Patient Revenue - Net were $965,000. Patient revenue represents revenues generated by the acquisition of HD on March 5, 2013.

Costs related to HMCA management and other fees segment for the three months ended March 31, 2013, were $3.5 million. For the three-month period ended March 31, 2012, costs were $3.3 million. Costs related to patient revenue - net were $791,000 for the quarter ended March 31, 2013.

Balance Sheet Items

Total assets doubled for the quarter ended March 31, 2013 to $73.3 million, a 118% increase, as compared to $33.6 million at June 30, 2012.

Total liabilities at March 31, 2013 were $38.3 million, a 70% increase as compared to $22.5 million at June 30, 2012.

Total current assets at March 31, 2013 were $39.7 million, a 54% increase as compared to $25.9 million at June 30, 2012.

At March 31, 2013, total cash and cash equivalents were $9.2 million, as compared to $12.0 million at June 30, 2012. This $2.8 million reduction was primarily due to the $6.2 million used in the acquisition of HDM.

Total current liabilities at March 31, 2013 were $24.3 million, a 15% increase as compared to $21.1 million at June 30, 2012.

Significant Events

The Company will hold its annual meeting on June 24, 2013. Dr. Raymond Damadian, president and chairman of FONAR Corporation, has issued his annual shareholder letter which can be seen on the Company's Web site at www.fonar.com/shareholder_letter.htm

On March 5, 2013, the Company and its subsidiary, Health Management Corporation of American (HMCA), acquired a majority interest (50.5%) in a newly formed limited liability company, Health Diagnostics Management (HDM). Prior to the acquisition, HMCA was managing 11 STAND-UP® MRI diagnostic centers -- 8 in New York and 3 in Florida, collectively completing 45,000 scans in 2012. In one giant step, HMCA grew by 14 MRI facilities under HMCA management -- 10 in New York and 4 in Florida, 12 of them equipped with STAND-UP® MRIs. Those 14 centers completed 68,000 MRI scans in 2012. Together the two groups of centers completed 113,000 scans in 2012, a strong indicator of the patient throughput run rate that is expected for HMCA going forward.

During the third quarter, the Company installed a new FONAR UPRIGHT®, Weight-Bearing, Multi-Position™ MRI in Texarkana, Texas. The Company has now installed 157 UPRIGHT® Multi-Position™ MRI scanners and they have performed approximately 2.75 million UPRIGHT® MRI scans worldwide.

On May 1, 2013, the Company repaid a portion of the Class A Stockholders capital contribution in the amount of $1.2 million. The Company's subsidiary, HMCA, now owns an 85% interest in Imperial Management Services. 

Management Commentary

Dr. Raymond Damadian, M.D., president and chairman of Fonar Corporation, said: "The acquisition of HDM is expected to be a significant source of profitability. With this acquisition we doubled the assets of the Company and tripled our stockholder's equity and book value. Funds were obtained for the $40 million acquisition from a commercial bank at a low interest rate."

"There are more reasons why this acquisition makes a lot of sense," continued Dr. Damadian. "By combining the resources of HMCA and HDM, we will enjoy the benefits of economies of scale, shared administrative and technical expertise and capabilities, and joint marketing strategies. HMCA's 11 STAND-UP® MRIs together with HDM's 12 form a network of 23 STAND-UP® MRIs, the largest in the world."

"Of course, we're not finished growing," said Dr. Damadian. "We will continue to pursue additional management contracts, primarily in New York and Florida."

"This past April 6th we held 'Symposium 2013' in New York City. The symposium was called 'The Cranio-Cervical Syndrome (CCS): The Vulnerability of the Human Neck and Its Impact on Cerebrospinal Fluid (CSF) Flow'," said Dr. Damadian. "There is a pandemic dimension of injuries of the neck and head, including 1.2 million whiplash injuries each year in the United States, and the principal purpose of Symposium 2013 was to bring the existence of this Cranio-Cervical Syndrome to the medical community and general populace. We will publish, before year-end, a monograph containing the complete presentation of the eight faculty who presented at the conference. We will also place their presentations online."

"Our understanding of the Cranio-Cervical Syndrome (CCS) and the vulnerability of the human neck and its impact on cerebrospinal fluid (CSF) flow began with our research and findings on multiple sclerosis. On September 20, 2011, I and co-author, FONAR scientist David Chu, PhD., published a paper titled 'The Possible Role of Cranio-Cervical Trauma and Abnormal CSF Hydrodynamics in the Genesis of Multiple Sclerosis,' in the journal Physiological Chemistry and Physics and Medical NMR (Sept. 20, 2011, 41: 1-17), found at http://www.fonar.com/. With this new understanding of the role that cervical trauma plays in the etiology of disease, it is imperative to certify that the sustained neck or head injuries of professional athletes such as NFL football players, whiplash patients and others with severe neck trauma, have not resulted in any obstructions of CSF flow, which would eventually lead to the symptomatology we have reported as related to the Cranio-Cervical Syndrome," said Dr. Damadian.

"The Company is fortunate to have as its flagship product the FONAR UPRIGHT® Multi-Position™ MRI," continued Dr. Damadian. "This is truly a unique technology producing exquisite images in all positions of the body. It not only yields a whole new treasure of new medical applications in such calamitous medical categories as multiple sclerosis, and other dementia, but it also possesses the strong potential to provide fresh new insights into the debilitating chronic consequences of sports injuries, the current epidemic of automobile whiplash injuries, all spine injuries, and more diseases yet to be unearthed."

About FONAR

FONAR (NASDAQ: FONR), Melville, NY, The Inventor of MR Scanning™, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world's first commercial MRI in 1980, and went public in 1981. Since its inception, nearly 300 recumbent-OPEN MRIs and 157 UPRIGHT® Multi-Position™ MRI scanners have been installed worldwide. FONAR's stellar product is the UPRIGHT® MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often sees the patient's problem that other scanners cannot because they are lie-down only. The patient-friendly UPRIGHT® MRI has a near-zero claustrophobic rejection rate by patients. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while they watch a 42" flat screen TV. FONAR is headquartered on Long Island, New York.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.

 
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED, except shares and per share data)
(UNAUDITED)
 
ASSETS
 
Current Assets:   March 31,
2013
  June 30,
2012
Cash and cash equivalents   $ 9,243   $ 12,032
Accounts receivable - net     4,993     5,095
Accounts receivable - related party     30     -
Medical receivables - net     4,513     -
Management and other fees receivable - net     14,820     3,782
Management and other fees receivable - related medical practices - net     2,396      1,311
Costs and estimated earnings in excess of billings on uncompleted contracts     488     1,129
Inventories     2,284     2,195
Current portion of notes receivable - net     118     116
Prepaid expenses and other current assets     837     206
Total Current Assets     39,722     25,866
Property and equipment - net     17,713     3,173
Notes receivable     192     276
Goodwill     1,667     -
Other intangible assets - net     12,796     3,835
Other assets     1,191     465
Total Assets   $ 73,281   $ 33,615
             
LIABILITIES AND STOCKHOLDERS' EQUITY
 
Current Liabilities:   March 31,
2013
  June 30,
2012
  Current portion of long-term debt and capital leases   $ 2,517   $ 1,854
  Accounts payable     2,639     2,077
  Other current liabilities     8,680     7,693
  Unearned revenue on service contracts     5,681     5,475
  Unearned revenue on service contracts - related party     28     -
  Customer advances     4,763     3,881
  Income tax payable     -     100
    Total Current Liabilities     24,308     21,080
Long-Term Liabilities:            
  Accounts payable, non current     -     47
  Due to related medical practices     231     229
  Long-term debt and capital leases, less current portion     13,404     777
  Other liabilities     362     401
    Total Long-Term Liabilities     13,997     1,454
    Total Liabilities     38,305     22,534
             
   
FONAR CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(000's OMITTED, except shares and per share data)  
(UNAUDITED)  
LIABILITIES AND STOCKHOLDERS' EQUITY (Continued)  
   
LIABILITIES AND STOCKHOLDERS' EQUITY (continued)

STOCKHOLDERS' EQUITY:
  March 31,
2013
    June 30,
2012
 
Class A non-voting preferred stock $.0001 par value; 453,000 shares authorized at March 31, 2013 and June 30, 2012, 313,438 issued and outstanding at March 31, 2013 and June 30, 2012     -       -  
                 
Preferred stock $.001 par value; 567,000 shares authorized at March 31, 2013 and June 30, 2012, issued and outstanding - none     -      
-
 
                 
Common Stock $.0001 par value; 8,500,000 shares authorized at March 31, 2013 and June 30, 2012, 5,977,905 and 5,912,905 issued at March 31, 2013 and June 30, 2012, respectively; 5,966,262 and 5,901,262 outstanding at March 31, 2013 and June 30, 2012, respectively    
1
      1  
                 
Class B Common Stock (10 votes per share) $.0001 par value; 227,000 shares authorized at March 31, 2013 and June 30, 2012, 158 issued and outstanding at March 31, 2013 and June 30, 2012    
-
     
-
 
                 
Class C Common Stock (25 votes per share) $.0001 par value; 567,000 shares authorized at March 31, 2013 and June 30, 2012, 382,513 issued and outstanding at March 31, 2013 and June 30, 2012    
 -
      -  
                 
Paid-in capital in excess of par value     174,478       174,084  
Accumulated other comprehensive loss     (15 )     (20 )
Accumulated deficit     (164,457 )     (168,334 )
Notes receivable from employee stockholders     (57 )     (71 )
Treasury stock, at cost - 11,643 shares of common stock at March 31, 2013 and June 30, 2012     (675 )     (675 )
Non controlling interests     25,701       6,096  
                 
Total Stockholders' Equity     34,976       11,081  
                 
Total Liabilities and Stockholders' Equity   $ 73,281     $ 33,615  
                 
   
FONAR CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)  
(000's OMITTED, except shares and per share data)  
   
REVENUES   FOR THE THREE MONTHS ENDED
MARCH 31,
 
    2013     2012  
  Product sales - net   $ 416     $ 1,309  
  Service and repair fees - net     2,867       3,008  
  Service and repair fees - related parties - net     27       27  
  Patient revenue - net     965       -  
  Management and other fees - net     5,402       3,601  
  Management and other fees - related medical practices - net     1,965       1,571  
    Total Revenues - Net     11,642       9,516  
COSTS AND EXPENSES                
  Costs related to product sales     498       962  
  Costs related to service and repair fees     819       891  
  Costs related to service and repair fees - related parties     8       8  
  Costs related to patient revenue     791       -  
  Costs related to management and other fees     2,606       2,390  
  Costs related to management and other fees - related medical practices     900       953  
  Research and development     381       315  
  Selling, general and administrative     3,774       2,224  
  Provision for bad debts     235       170  
    Total Costs and Expenses     10,012       7,913  
Income From Operations     1,630       1,603  
Interest Expense     (79 )     (103 )
Investment Income     55       53  
Income Before Provision for Income Taxes     1,606       1,553  
Provision for Income Taxes     25       -  
Net Income     1,581       1,553  
Net Income - Non Controlling Interests     505       261  
Net Income - Controlling Interests   $ 1,076     $ 1,292  
Net Income Available to Common Stockholders   $ 1,005     $ 1,206  
Net Income Available to Class A Non-Voting Preferred Stockholders   $ 53     $ 64  
Net Income Available to Class C Common Stockholders   $ 18     $ 22  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.17     $ 0.21  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.17     $ 0.20  
Basic and Diluted Income Per Share-Common C   $ 0.05     $ 0.06  
Weighted Average Basis Shares Outstanding     5,937,096       5,836,229  
Weighted Average Diluted Shares Outstanding     6,064,600       5,963,733  
Weighted Average Basic Shares Outstanding - Class C Common     382,513       382,513  
Weighted Average Diluted Shares Outstanding - Class C Common     382,513       382,513  
                 
   
FONAR CORPORATION AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)  
(000's OMITTED, except shares and per share data)  
   
REVENUES   FOR THE NINE MONTHS ENDED
MARCH 31,
 
    2013     2012  
  Product sales - net   $ 2,536     $ 4,699  
  Service and repair fees - net     8,341       8,720  
  Service and repair fees - related parties - net     83       83  
  Patient revenue - net     965       -  
  Management and other fees - net     12,946       10,238  
  Management and other fees - related medical practices - net     5,895       4,712  
  Total Revenues - Net     30,766       28,452  
COSTS AND EXPENSES                
  Costs related to product sales     2,457       3,608  
  Costs related to service and repair fees     2,579       2,572  
  Costs related to service and repair fees - related parties     26       24  
  Costs related to patient revenue     791       -  
  Costs related to management and other fees     7,013       6,462  
  Costs related to management and other fees - related medical practices     2,568       2,673  
  Research and development     1,031       938  
  Selling, general and administrative     8,338       6,261  
  Provision for bad debts     735       655  
  Total Costs and Expenses     25,538       23,193  
Income From Operations     5,228       5,259  
Interest Expense     (258 )     (333 )
Investment Income     174       178  
Other (Expense) Income     (13 )     55  
Income Before Provision for Income Taxes     5,131       5,159  
Provision for Income Taxes     152       21  
Net Income     4,979       5,138  
Net Income - Non Controlling Interests     1,103       796  
Net Income - Controlling Interests   $ 3,876     $ 4,342  
Net Income Available to Common Stockholders   $ 3,621     $ 4,051  
Net Income Available to Class A Non-voting Preferred Stockholders   $ 190     $ 217  
Net Income Available to Class C Common Stockholders   $ 65     $ 74  
Basic Net Income Per Common Share Available to Common Stockholders   $ 0.61     $ 0.71  
Diluted Net Income Per Common Share Available to Common Stockholders   $ 0.60     $ 0.69  
Basic and Diluted Income Per Share-Common C   $ 0.17     $ 0.19  
Weighted Average Basic Shares Outstanding     5,921,540       5,744,506  
Weighted Average Diluted Shares Outstanding     6,049,044       5,872,010  
Weighted Average Basic Shares Outstanding - Class C Common     382,513       382,513  
Weighted Average Diluted Shares Outstanding - Class C Common     382,513       382,513  
                 

Contact Information